GlaxoSmithKline (GSK) Reports Q3 EPS of GBP0.36

GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of GBP0.36, better than the analyst estimate of GBP0.33. Revenue for the quarter came in at GBP8.1 billion versus the consensus estimate of GBP8.01 billion.

• Now expect 2018 Adjusted EPS growth of 8-10% CER

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping bid, calls offer below NAV
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy